SCHEMBL8203043

SCHEMBL8203043

C=CCC(C)(C)COC(=O)N[C@H](C(=O)OC)C1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
CASP1 P29466 1/20 0.36
EPHX1 P07099 3/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
CCR2 P41597 1/20 0.33
EPHX2 P34913 1/20 0.33
TSHR P16473 2/20 0.32
LMNA P02545 1/20 0.32
CYP3A4 P08684 1/20 0.32
NFKB1 P19838 1/20 0.32
ADRA1A P35348 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TP53 P04637 1/20 0.32
AAK1 Q2M2I8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1244162 0.90 CASP1 (0.38) ALDH1A1NPSR1CASP1EPHX1GAA
SCHEMBL733205 0.90 CASP1 (0.38) ALDH1A1NPSR1CASP1EPHX1GAA
SCHEMBL731388 0.89 CASP1 (0.36) ALDH1A1NPSR1CASP1EPHX1GAA
SCHEMBL1244172 0.89 CASP1 (0.36) ALDH1A1NPSR1CASP1EPHX1GAA
SCHEMBL16257926 0.87 ALDH1A1 (0.36) ALDH1A1NPSR1CASP1EPHX1GAA
SCHEMBL16502012 0.82 PEPD (0.40) ALDH1A1RAB9ATSHRLMNACYP3A4
SCHEMBL8096010 0.81 PEPD (0.41) ALDH1A1RAB9ATSHRLMNACYP3A4
SCHEMBL733596 0.79 CASP1 (0.39) ALDH1A1NPSR1CASP1GAARAB9A
SCHEMBL732029 0.78 CASP1 (0.39) ALDH1A1NPSR1CASP1GAARAB9A
SCHEMBL8246560 0.77 FKBP1A (0.43) ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309540-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2012-11-13 US disclosed
US-8309540-B2 HCV NS3 protease inhibitors MERCK SHARP & DOHME CORP. (US) 2012-11-13 US disclosed
US-20100093779-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2010-04-15 US disclosed
US-20100093779-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME LLC 2010-04-15 US disclosed
WO-2008051514-A2 HCV NS3 PROTEASE INHIBITORS MERCK & CO., INC. (US) 2008-05-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093779-A1 HCV NS3 PROTEASE INHIBITORS HAVCR2, GTF3C3, CTSC ALDH1A1 1199/4885NPSR1 4083/4885CASP1 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.